pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.

Name: pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Author: Jones, Gemma N

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. — المؤلف: Jones, Gemma N — British journal of cancer 20190913

المؤلف: Jones, Gemma N
النشر: British journal of cancer 20190913
الوصف: 1233-1243 p.
الموضوعات: Animals؛ Antineoplastic Agents؛ Ataxia Telangiectasia Mutated Proteins؛ Biomarkers؛ Cell Line؛ DNA Damage؛ Humans؛ Immunohistochemistry